Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan notifications rather than financial performance results.
Material Changes
The filing details an increase in notional interests in Ordinary Shares and American Depositary Shares (ADSs) for specific connected persons following the notional re-investment of the dividend paid on April 11, 2013. The transaction prices were 1565.50 pence per Ordinary Share and $48.52 per ADS.
- Dr M M Slaoui / Dr K Slaoui: 28.847 Ordinary Shares
- Mr P C Thomson / Mrs K Thomson: 27.347 Ordinary Shares
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or risk factors. It notes that notional dividends accrued will be paid out in proportion to the percentage of the participant's Performance Share Plan holdings that vest following the end of the relevant three-year measurement period. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Investor Verification Points
- Verify the vesting schedule and conditions for the 2009 Performance Share Plan to understand future payout obligations.
- Confirm the exact number of ADSs held by the connected persons, as the filing lists Ordinary Shares but mentions ADS pricing.
- Review the full dividend reinvestment policy to assess the impact on executive compensation structures.